Cookies on this site

Professor Carl Heneghan, Director of the Centre for Evidence Based Medicine in NDPCHS, recently presented his research on oral hormone pregnancy tests to members of Parliament.

Professor Neil Vargesson, University of Aberdeen; Yasmin Qureshi MP, Chair of the APPG on Primodos; Marie Lyon, Chair of the Association of Children Damaged by Hormone Pregnancy Tests; Professor Carl Heneghan, University of Oxford

Professor Carl Heneghan, Director of the Centre for Evidence Based Medicine in NDPCHS, presented his research on oral hormone pregnancy tests to members of Parliament, reigniting discussions about a drug that may have caused birth defects decades ago. 

Invited by Yasmin Qureshi MP, chair of the All-Party Parliamentary Group on Hormone Pregnancy Tests, Heneghan detailed his systematic review and meta-analysis of studies concerning Primodos, a hormone pregnancy test used between 1958 and 1978. 

To find out if they were pregnant, women would take the Primodos pill and hormones in the drug would induce a period if the woman was not pregnant, but thousands who used it gave birth to children with congenital malformations. 

The research led by Professor Heneghan, first published in 2018, analysed 26 studies involving 71,330 women, revealing a potential link between oral hormone pregnancy tests and increased risks of congenital malformations. Specifically, the study found associations with heart defects, nervous system abnormalities, and musculoskeletal malformations. 

During his presentation, Professor Heneghan emphasized the importance of comprehensive data analysis, highlighting discrepancies in previous government-commissioned reviews. His meta-analysis suggested a statistically significant correlation between hormone pregnancy tests and birth defects, a finding that challenges earlier regulatory assessments. 

The presentation comes six years after the research by Professor Heneghan first sparked parliamentary debates and calls for a thorough review of historical medical practices. 

Campaigners like Marie Lyon, whose daughter was born with a shortened arm after Marie used Primodos, view Heneghan's ongoing work as crucial in seeking justice and understanding potential medical oversights. 

The event underscores the persistent questions surrounding Primodos and highlights the ongoing efforts to understand historical pharmaceutical risks. 

 

To learn more about Primodos and the systematic review and meta-analysis by Professor Heneghan et al. visit our timeline of The Primodos Story.  

Similar stories

The Glastonbury of EBM inspires and showcases the next generation of EBM leaders

The mission of this year’s EBMLive, the 11th major evidence-live themed conference since the inaugural event in 2011, was to offer a platform that encouraged debate and learning on the current status and future directions of Evidence-Based Medicine (EBM), actively disseminating and translating evidence in health care. Was this mission accomplished?

Oxford Medical Students publish new findings through CEBM training

Oxford Medical Students who participated in the Centre for Evidence-Based Medicine’s Special Study Theme (SST) have published new findings in a peer-reviewed journal, demonstrating the strength of the programme in equipping undergraduates to produce high-quality, clinically relevant research.

Preventing Overdiagnosis (POD) Conference 2025

Highlights and key takeaways from our gathering of global expertise in Oxford, building on the momentum of previous conferences since the first small gathering in 2012.

Professor Carl Heneghan presents evidence on the health impacts of breast implants at UK parliamentary Women and Equalities Committee

Professor Carl Heneghan, Director of the Centre for Evidence-Based Medicine and co-Director of the DPhil in Evidence-Based Health Care at Oxford University joined other academics and medical professionals to provide evidence on the health impacts of breast implants during a Women and Equalities Committee (WEC) all evidence session in Parliament on Wednesday, 14 May 2025.

Members of CEBM and the Oxford Tobacco Addiction Group (OxTAG) share their work at key conference in New Orleans.

CEBM members and affiliates who are part of the Oxford Tobacco Addiction Group team (OxTAG) shared their smoking/vaping cessation research work at the annual Society for Research on Nicotine and Tobacco (SRNT) conference in New Orleans earlier this month.

New study identifies text messaging and varenicline as promising approaches for vaping cessation

With 5.1 million people in Great Britain using vapes, what support is there to help people quit? New research explores the best interventions currently available.